At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 668 enrolled
Drug / intervention
Rosuvastatin +2 moredrug
Likely dose
Rosuvastatin 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Subjects With Type IIa and IIb Hypercholesterolaemia
In Brief
A Phase 4 clinical trial evaluating Rosuvastatin, Pravastatin, and 1 other intervention for Type IIa and IIb Hypercholesterolaemia. Completed, enrolled 668 participants across 170 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Rosuvastatin 5 mg as an hypercholesterolemia treatment comparatively at 2 other statins: Pravastatin 40 mg and Atorvastatin 10 mg. Treatment efficacy will be evaluated by the percentage of LDL-C variation after 8 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType IIa and IIb Hypercholesterolaemia
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedMar 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedMar 7, 2008
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.3 years ago
Interventions
Rosuvastatindrug
5mg oral
Pravastatindrug
40mg oral
Atorvastatindrug
10mg oral